Table 3.

Odds ratios for seroresponse rates at after trivalent influenza vaccination in patients with lung cancer or COPD.

		Crude analysis		Multivariate analysis*
	Seroresponse rate (sR) (≥4 fold-rise): n (%)	OR (95% CI)	P value	OR (95% CI)	P value
A/California/7/2009(H1N1)pdm09
Lung cancer	18 (72)	2.52 (0.70–9.79)	0.153	1.29 (0.27–6.29)	0.749
COPD	13 (50)	1.00 (ref.)		1.00 (ref.)
A/Texas/50/2012(H3N2)
Lung cancer	16 (64)	1.76 (0.51–6.35)	0.400	1.11 (0.30–4.15)	0.872
COPD	13 (50)	1.00 (ref.)		1.00 (ref.)
B/Massachusetts/02/2012
Lung cancer	15 (60)	1.49 (0.43–5.25)	0.577	1.02 (0.28–3.78)	0.975
COPD	13 (50)	1.00 (ref.)		1.00 (ref.)

^*Adjusted for age, gender, and prevaccination titer.